Combination therapy response biomarkers of colorectal cancer
Posted in the Colon Cancer Forum
#1 Feb 21, 2012
According to this recent US patent application, high pretreatment plasma YKL-40 and serum YKL-40 levels were prognostic biomarkers of short overall survival in two independent studies of patients with metastatic colorectal cancer treated with third-line cetuximab in combination with irinotecan. Details: http://www.sciclips.com/sciclips/biomarker-ne...
Add your comments below
|The 10 commandments of cancer prevention (May '09)||May '15||usherhollens||17|
|New blood tests, liquid biopsies, may transform...||May '15||New Perspective||1|
|High vitamin D levels increase survival of pati... (Jan '15)||Jan '15||Gerald Vonberger||1|
|Less invasive may be best way (Jan '14)||Apr '14||Deb||5|
|City of Toronto refuses to pay for funeral of u... (Jan '14)||Jan '14||wild child||8|
|FDA approves Amgen colon cancer drug Vectibix (Feb '07)||Nov '13||yoram||2|
|BLOG: Farrah Fawcett's Cancer Battle Raising Qu... (May '09)||Sep '13||bud_schmones||6|
Find what you want!
Search Colon Cancer Forum Now
Copyright © 2015 Topix LLC